Feedback / Questions
risvodetinib (IkT-148009) - Inhibikase, Clintrex, ABLi Therapeutics
https://www.globenewswire.com/news-release/2025/05/21/3085719/0/en/ABLi-Therapeutics-Announces-Details-of-the-End-of-Phase-2-Meeting-with-FDA-for-Evaluation-of-Risvodetinib-as-a-Treatment-for-Parkinson-s-Disease.html
May 21, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next